Jude Onyia Neurocrine Biosciences Inc (NBIX) insider trading activity

Jude Onyia is Chief Scientific Officer of NEUROCRINE BIOSCIENCES INC. Currently has a direct ownership of 15,881 shares of NBIX, which is worth approximately $2.3 Million. The most recent transaction as insider was on Nov 29, 2025, when has been sold 2,248 shares (Common Stock) at a price of $152.16 per share, resulting in proceeds of $342,055. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.9K

15.89% 3M change

2.8% 12M change

Total Value Held $2.3 Million

Jude Onyia Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 29 2025	SELL Payment of exercise price or tax liability	$342,055 $152.16 p/Share	2,248 Reduced 12.4%	15,881 Common Stock
Nov 29 2025	BUY Exercise of conversion of derivative security	-	4,426 Added 19.62%	18,129 Common Stock
Sep 03 2025	SELL Bona fide gift	-	1,470 Reduced 9.69%	13,703 Common Stock
Aug 05 2025	SELL Bona fide gift	-	3,116 Reduced 17.04%	15,173 Common Stock
Jul 09 2025	SELL Open market or private sale	$7,803,986 $130.46 p/Share	59,819 Reduced 76.58%	18,289 Common Stock
Jul 09 2025	BUY Exercise of conversion of derivative security	$5,069,062 $84.74 p/Share	59,819 Added 43.37%	78,108 Common Stock
Jul 02 2025	SELL Open market or private sale	$2,649,707 $130.13 p/Share	20,362 Reduced 52.68%	18,289 Common Stock

Jul 02 2025	BUY Exercise of conversion of derivative security	$1,725,475 $84.74 p/Share	20,362 Added 34.5%	38,651 Common Stock
Feb 13 2025	SELL Open market or private sale	$336,238 $116.79 p/Share	2,879 Reduced 13.73%	18,089 Common Stock
Feb 13 2025	BUY Exercise of conversion of derivative security	-	5,407 Added 21.68%	19,536 Common Stock
Jan 31 2025	SELL Open market or private sale	$19,274 $152.97 p/Share	126 Reduced 0.8%	15,561 Common Stock
Jan 31 2025	BUY Exercise of conversion of derivative security	-	238 Added 1.49%	15,687 Common Stock
Nov 29 2024	SELL Open market or private sale	$294,381 $126.29 p/Share	2,331 Reduced 13.11%	15,449 Common Stock
Nov 29 2024	BUY Exercise of conversion of derivative security	-	4,426 Added 19.93%	17,780 Common Stock
Feb 13 2024	SELL Open market or private sale	$190,370 $132.94 p/Share	1,432 Reduced 9.84%	13,128 Common Stock
Jan 31 2024	SELL Open market or private sale	$17,884 $141.94 p/Share	126 Reduced 1.05%	11,843 Common Stock
Nov 29 2023	SELL Open market or private sale	$264,731 $113.57 p/Share	2,331 Reduced 16.58%	11,732 Common Stock
Aug 21 2023	SELL Open market or private sale	$343,369 $107.37 p/Share	3,198 Reduced 24.91%	9,638 Common Stock
Feb 07 2023	SELL Open market or private sale	$461,168 $102.3 p/Share	4,508 Reduced 40.86%	6,525 Common Stock
Jan 31 2023	SELL Open market or private sale	$13,668 $108.48 p/Share	126 Reduced 4.84%	2,477 Common Stock
Nov 29 2022	SELL Open market or private sale	$284,148 $121.9 p/Share	2,331 Reduced 49.63%	2,366 Common Stock

Also insider at

VYGR

Voyager Therapeutics, Inc. Healthcare

Director

Jude Onyia

Chief Scientific Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NBIX shares.

Notify only if

Value

Insider Trading

Get notified when an Neurocrine Biosciences Inc insider buys or sells NBIX shares.

Notify only if

Operation

Value

Type

News

Receive news related to NEUROCRINE BIOSCIENCES INC

Track Activities on NBIX

Account